2 Breast Cancer Fighting Stocks to Invest In
The San Antonio Breast Cancer Symposium (SABCS) transformed over the past few years into one of the biggest venues for companies releasing data on promising new drug candidates. Breast cancer remains one of the most common forms of cancer globally. Thanks to many new treatment options over the past decade, long-term survival has grown dramatically.
Among the many presentations on the docket at SABCS from Dec. 10 to 14, pivotal trial results stand out for Athenex's (NASDAQ: ATNX) oral paclitaxel and Seattle Genetics' (NASDAQ: SGEN) tucatinib. Both companies have already heralded their trials as successes; this will be the first public airing of the details.
Image source: Getty Images.
Source Fool.com
